All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, BeOne Medicines, Johnson & Johnson, Roche, and Sobi, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
Brentuximab vedotin plus CHP is approved by the European Commission and China for the treatment of adult patients with sALCL
On May 14, 2020, brentuximab vedotin in combination with cyclophosphamide, doxorubicin, prednisone (CHP) was granted an extension on the current conditional marketing authorization by the European Commission for treatment of adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL). Brentuximab vedotin has previously received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use.1
The European Commission approval was based on positive data from ECHELON-2 phase III trial (NCT01777152). The trial evaluated brentuximab vedotin plus CHP vs cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) as first-line treatment in patients with CD30+ peripheral T-cell lymphoma, which included the sALCL subtype. The ECHELON-2 trial met its primary endpoint and demonstrated a statistically significant improvement in progression-free survival with brentuximab vedotin plus CHP (HR, 0.71; p = 0.0110).1
The safety profile from the ECHELON-2 study was comparable between the two treatment arms and consistent with the established safety profile of brentuximab vedotin combined with chemotherapy.1
China
Brentuximab vedotin has also been granted fast-track approval by China’s National Medical Products Administration for the treatment of adult patients with relapsed or refractory sALCL or CD30+ Hodgkin lymphoma. The approval was also based on the results from the ECHELON-2 trial.2
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
Which of the following would most increase your confidence in referring patients with R/R large B-cell lymphoma for CAR T-cell therapy?